Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Tracy Todd Batchelor, M.D.

Co-Author

This page shows the publications co-authored by Tracy Batchelor and Jay Loeffler.
Connection Strength

2.445
  1. Primary CNS lymphoma. J Clin Oncol. 2006 Mar 10; 24(8):1281-8.
    View in: PubMed
    Score: 0.345
  2. Performance of a Hospital Pathway for Patients With a New Single Brain Mass. J Oncol Pract. 2019 Mar; 15(3):e211-e218.
    View in: PubMed
    Score: 0.211
  3. The role of whole brain radiation in primary CNS lymphoma. Blood. 2016 07 07; 128(1):32-6.
    View in: PubMed
    Score: 0.175
  4. Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii12.
    View in: PubMed
    Score: 0.153
  5. Low-grade gliomas. Oncologist. 2014 Apr; 19(4):403-13.
    View in: PubMed
    Score: 0.151
  6. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):19059-64.
    View in: PubMed
    Score: 0.147
  7. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23.
    View in: PubMed
    Score: 0.115
  8. Phase Ib study of cediranib in combination with daily temozolomide and radiation in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13010.
    View in: PubMed
    Score: 0.108
  9. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol. 2009 Apr; 6(4):229-36.
    View in: PubMed
    Score: 0.107
  10. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007 Aug; 8(8):610-22.
    View in: PubMed
    Score: 0.095
  11. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan; 11(1):83-95.
    View in: PubMed
    Score: 0.091
  12. Genetic analyses for predictors of radiation response in glioblastoma. Int J Radiat Oncol Biol Phys. 2005 Nov 01; 63(3):704-10.
    View in: PubMed
    Score: 0.082
  13. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol. 2005 Mar 01; 23(7):1507-13.
    View in: PubMed
    Score: 0.080
  14. Primary dural lymphomas: Clinical presentation, management, and outcome. Cancer. 2020 06 15; 126(12):2811-2820.
    View in: PubMed
    Score: 0.057
  15. Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. Neuro Oncol. 2019 09 06; 21(9):1118-1130.
    View in: PubMed
    Score: 0.055
  16. Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma. Radiother Oncol. 2019 08; 137:95-101.
    View in: PubMed
    Score: 0.054
  17. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide. J Neurooncol. 2019 Mar; 142(1):69-77.
    View in: PubMed
    Score: 0.052
  18. Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series. Neurooncol Pract. 2018 Mar; 5(1):64-68.
    View in: PubMed
    Score: 0.047
  19. Neurocognitive effects of proton radiation therapy in adults with low-grade glioma. J Neurooncol. 2016 Jan; 126(1):157-164.
    View in: PubMed
    Score: 0.043
  20. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol. 2015 Apr 01; 33(10):1197-213.
    View in: PubMed
    Score: 0.040
  21. Proton therapy for low-grade gliomas: Results from a prospective trial. Cancer. 2015 May 15; 121(10):1712-9.
    View in: PubMed
    Score: 0.040
  22. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014 Nov; 4(11):1299-309.
    View in: PubMed
    Score: 0.039
  23. Long-term outcomes of patients with spinal cord gliomas treated by modern conformal radiation techniques. Int J Radiat Oncol Biol Phys. 2011 Sep 01; 81(1):232-8.
    View in: PubMed
    Score: 0.030
  24. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol. 2010 Sep; 31(7):1135-43.
    View in: PubMed
    Score: 0.029
  25. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009 Jun; 6(6):327-38.
    View in: PubMed
    Score: 0.027
  26. Treatment of progressive neurofibromatosis type 2-related vestibular schwannoma with erlotinib. J Clin Oncol. 2008 May 20; 26(15_suppl):2045.
    View in: PubMed
    Score: 0.025
  27. Characterization of blood vessels in brain autopsies of GBM patients who received antiangiogenic treatment. J Clin Oncol. 2008 May 20; 26(15_suppl):2009.
    View in: PubMed
    Score: 0.025
  28. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J Neurooncol. 2008 May; 88(1):43-50.
    View in: PubMed
    Score: 0.025
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.